Phibro Animal Health

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment consists of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Earnings data Q3 2024

PAHC reports Q3 sales growth, addresses challenges and opportunities

PAHC's Q3 2023 earnings call highlighted strong sales growth in the Animal Health segment, while facing challenges in the Mineral Nutrition segment. The company reiterated its full-year guidance and discussed various opportunities for growth and expansion.

Phibro Animal Health Corporation reports solid Q2 earnings and projects sustained growth for fiscal year 2024

Phibro Animal Health Corporation delivered solid sales and EBITDA growth, particularly driven by the Animal Health segment. While facing challenges in free cash flow, the company is strategically positioned to capitalize on opportunities for sustained growth in fiscal year 2024.

Phibro Animal Health Corporation reports mixed Q3 performance and reduced guidance

Phibro Animal Health Corporation's Q3 2023 performance reflected strength in the core Animal Health business but challenges in the Mineral Nutritional business. The company expressed confidence in its products despite regulatory actions and provided updated guidance reflecting reduced expectations for the fiscal year.

Phibro Animal Health Corporation reports 2% increase in Q4 net sales, affirms full-year guidance

Phibro Animal Health Corporation's Q4 2023 performance demonstrated overall growth in consolidated net sales, particularly driven by the Animal Health segment. The company's affirmation of its full-year guidance and positive trends in underlying demand reflect confidence in its financial outlook. While facing challenges in certain product segments and international markets, the company remains optimistic about opportunities for growth and global demand for its products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 8, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 9, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-202.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock?

Why Is Phibro (PAHC) Up 12.7% Since Last Earnings Report?

Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.

Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales

Is Phibro Animal Health (PAHC) a Great Value Stock Right Now?

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Global Healthcare Conference. Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on Tuesday, March 12, 2024, at 4:35 PM ET at the Loews Miami Beach Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investo.

Phibro Animal Health Corporation to Participate in Barclays Global Healthcare Conference

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2024 Virtual Animal Health Summit. Chief Financial Officer, Glenn David along with EVP Corporate Strategy, Dani Bendheim will address financial analysts and investors on Thursday, February 29, 2024, at 10:00 AM ET. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A.

Phibro Animal Health Corporation to Participate in Bank of America 2024 Animal Health Summit

Phibro (PAHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Phibro (PAHC) a New Buy Stock

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

Phibro Animal Health Corporation (PAHC) Q2 2024 Earnings Call Transcript

Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.

Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Phibro (PAHC) Reports Q2 Earnings: What Key Metrics Have to Say

Phibro Animal Health (PAHC) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.34 per share a year ago.

Phibro Animal Health (PAHC) Surpasses Q2 Earnings and Revenue Estimates

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) Net sales of $249.9 million, an increase of $5.3 million, or 2% Net income of $1.3 million, a decrease of $5.9 million Diluted ea.

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 27, 2024, to stockholders of record at the close of business on March 6, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with liv.

Phibro Animal Health Corporation Declares Quarterly Dividend

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024. Mr. Richard Johnson, who is currently serving as Phibro's interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with his successor. Mr. David brings ove.

Phibro Animal Health Corporation Announces Chief Financial Officer Changes

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 7, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 8, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (8.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

Why Is Phibro (PAHC) Up 13.6% Since Last Earnings Report?

Phibro Animal Health Corporation is expected to experience net sales growth and net income growth in the coming years. The company has a healthy balance sheet with little debt, which positions it well for successful expansion and innovation in its products. There are risks from changing regulations and competition, but overall, Phibro Animal appears undervalued.

Phibro Animal Health: Vaccine App And Analysts' Expectations Imply Undervaluation

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q1 2024 Earnings Conference Call November 9, 2023 9:00 AM ET Company Participants Daniel M. Bendheim - EVP, Corporate Strategy Jack C.

Phibro Animal Health Corporation (PAHC) Q1 2024 Earnings Call Transcript

Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.

Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down

While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

News for Phibro Animal Health Stock (PAHC)